These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1102243)

  • 21. Talking about Toxicity - "What We've Got Here Is a Failure to Communicate".
    Sacks CA; Miller PW; Longo DL
    N Engl J Med; 2019 Oct; 381(15):1406-1408. PubMed ID: 31597018
    [No Abstract]   [Full Text] [Related]  

  • 22. The case for recording events in clinical trials.
    Skegg DC; Doll R
    Br Med J; 1977 Dec; 2(6101):1523-4. PubMed ID: 338116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fundamental principles of clinical trials].
    Skarke C; Geisslinger G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):401-7. PubMed ID: 15830250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role and significance of clinico-pharmacological investigations in drug research].
    Simon K
    Acta Pharm Hung; 1978; 48 Suppl():44-9. PubMed ID: 373387
    [No Abstract]   [Full Text] [Related]  

  • 25. Iatrogenic disease: an epidemiologic perspective.
    Sartwell PE
    Int J Health Serv; 1974; 4(1):89-93. PubMed ID: 4829900
    [No Abstract]   [Full Text] [Related]  

  • 26. Detection of drug-induced disease.
    Lawson DH
    Br J Clin Pharmacol; 1979 Jan; 7(1):13-8. PubMed ID: 367408
    [No Abstract]   [Full Text] [Related]  

  • 27. The issue of side effects and the "blind ability" of clinical drug trials.
    Katz R; Deveaugh-Geiss J
    Am J Psychiatry; 1993 Nov; 150(11):1759-60; author reply 1760-1. PubMed ID: 8214202
    [No Abstract]   [Full Text] [Related]  

  • 28. The issue of side effects and the "blind ability" of clinical drug trials.
    Duberstein PR
    Am J Psychiatry; 1993 Nov; 150(11):1760; author reply 1760-1. PubMed ID: 8214203
    [No Abstract]   [Full Text] [Related]  

  • 29. Towards rational drug therapy in old age. The F.E. Williams Lecture 1985.
    Caird FI
    J R Coll Physicians Lond; 1985 Oct; 19(4):235-9. PubMed ID: 4067897
    [No Abstract]   [Full Text] [Related]  

  • 30. Minimum acceptable requirements for introduction and marketing of drugs.
    Lasagna L
    Drugs; 1974; 7(6):409-13. PubMed ID: 4422210
    [No Abstract]   [Full Text] [Related]  

  • 31. Unapproved drug use: compassionate or cause for concern?
    Ross E
    Lancet Neurol; 2009 Feb; 8(2):136-7. PubMed ID: 19161905
    [No Abstract]   [Full Text] [Related]  

  • 32. Post-marketing surveillance: drug epidemiology.
    Borden EK
    J Int Med Res; 1981; 9(6):401-7. PubMed ID: 7319130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compensation and drug trials.
    Diamond AL; Laurence DR
    Br Med J (Clin Res Ed); 1983 Sep; 287(6393):675-7. PubMed ID: 6411277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can postmarketing surveillance help to effect optimal drug therapy?
    Strom BL; Melmon KL
    JAMA; 1979 Nov; 242(22):2420-2. PubMed ID: 385922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trials: use of a clinical tumor panel and overview of current resources and studies.
    Muggia FM; Rozencweig M; Chiuten DF; Jensen-Akula MS; Charles LM; Kubota TT; Bono VH
    Cancer Treat Rep; 1980 Jan; 64(1):1-9. PubMed ID: 6991100
    [No Abstract]   [Full Text] [Related]  

  • 36. [Drug testing today].
    Domschke S; Domschke W
    Fortschr Med; 1981 Jun; 99(21):814-8. PubMed ID: 7250872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Principles of controlled trials (author's transl)].
    Fink H
    Arzneimittelforschung; 1978; 28(11a):2017-9. PubMed ID: 383091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The promise of pharmacoepidemiology.
    Strom BL
    Annu Rev Pharmacol Toxicol; 1987; 27():71-86. PubMed ID: 3555321
    [No Abstract]   [Full Text] [Related]  

  • 39. Consider drug efficacy before first-in-human trials.
    Kimmelman J; Federico C
    Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cost evaluation of a side-effect of a drug].
    Royer RJ; Vidrequin A; Trechot P; Boissel P; Netter P
    Presse Med; 1990 Jun; 19(26):1240. PubMed ID: 2142776
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.